# New York Blood Center Enterprises – FDA 483, Jul 8, 2026

Source: https://www.keypedia.com/records/483/new-york-blood-center-enterprises/13ccab19-2fff-4f33-bc8f-a1a3d7759b9b

> FDA 483 for New York Blood Center Enterprises on July 08, 2026. Product: biologics. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: New York Blood Center Enterprises
- Inspection Date: 2026-07-08
- Product Type: biologics
- Office Name: New York District Office
- Summary: An FDA inspection of New York Blood Center Enterprises in Westbury, NY, revealed four observations related to the handling and record-keeping of blood products. Deficiencies included failure to follow standard operating procedures for temperature control during blood product processing and distribution, use of damaged equipment for temperature checks, and inadequate record maintenance for blood product inventory and ISBT labels. These issues indicate a need for improved adherence to established procedures and record-keeping practices.

## Related Documents

- [483 - 2023-10-27](https://www.keypedia.com/records/483/new-york-blood-center-enterprises/6374025e-491d-4250-aeb6-7b4b9c91644a) — date: October 27, 2023

## Related Officers

- [Investigator](https://www.keypedia.com/people/irina-gaberman/c863b2de-4c64-40d2-a390-289d293e5a8f)

Company: https://www.keypedia.com/companies/new-york-blood-center-enterprises/9a6a3572-57ad-4dc4-977f-d38116628d8c

Office: https://www.keypedia.com/offices/new-york-district-office/9fa3d265-16ca-438d-8a6e-b47f60dc260d